(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 85.73% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Precigen's revenue in 2026 is $85,717,000.On average, 6 Wall Street analysts forecast PGEN's revenue for 2026 to be $87,178,002,292, with the lowest PGEN revenue forecast at $71,650,013,630, and the highest PGEN revenue forecast at $107,142,047,665. On average, 6 Wall Street analysts forecast PGEN's revenue for 2027 to be $161,978,726,095, with the lowest PGEN revenue forecast at $107,646,877,363, and the highest PGEN revenue forecast at $260,900,284,489.
In 2028, PGEN is forecast to generate $187,005,389,861 in revenue, with the lowest revenue forecast at $130,876,204,188 and the highest revenue forecast at $243,231,245,049.